S&P 500
$5,802.82
-0.7%
-$39.19
DJI
$41,603.07
-0.6%
-$256.02
NASDAQ
$18,737.21
-1.0%
-$188.53
Bitcoin
107,833.00
-2.6%
-2,908.23
AAPL
$195.55
-2.9%
-$5.81
AMZN
$201.33
-0.9%
-$1.77
GOOG
$169.68
-1.3%
-$2.30
META
$627.70
-1.4%
-$8.87
MSFT
$451.11
-0.8%
-$3.75
NVDA
$131.48
-1.0%
-$1.36
TSLA
$339.93
-0.3%
-$1.11
Tarsus Pharmaceuticals (NASDAQ: TARS)
$43.09
(0.3%)
$0.12
Price as of May 23, 2025, 3:58 p.m. ET
Tarsus Pharmaceuticals Return vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
Tarsus Pharmaceuticals Company Info
Tarsus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which focuses on the development and commercialization of therapeutic candidates. Its product candidate, TP-03, is a novel therapeutic in Phase 2b/3 that is being developed for the treatment of blepharitis caused by the infestation of Demodex mites, which is referred to as Demodex blepharitis. The company was founded by Bobak Azamian and D. Michael Ackermann in 2017 and is headquartered in Irvine, CA.
Valuation
Related Stocks
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.